Key facts
- DeepLife’s last known valuation is $40.9M (Dec 2024).
- It has raised $11.8M; the latest was Later Stage VC ($9.9M) in Dec 2024.
- Notable investors include Creative Destruction Lab, Kima Ventures, Entrepreneurs First, Turenne Groupe, Aloe Private Equity — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for DeepLife
- ·The full record, as it builds
Funding rounds
No funding rounds for DeepLife are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DeepLife
Developer of a learning-powered platform designed to accelerate cell engineering and target identification in biotech and pharmaceutical research. The company offers a software-as-a-service platform that integrates multi-omics sequencing data, cell atlases, and proprietary deep learning tools, enabling researchers to simulate cell behavior in silico, identify molecular triggers, and optimize cell engineering processes efficiently.
- Sector
- Healthcare
- HQ
- Vernon, France
- Founded
- 2019
- Employees
- 33
- Website
- deeplife.co/
- Ownership
- Privately Held (backing)
DeepLife doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DeepLife shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DeepLife in its N-PORT filings yet. We sweep new filings monthly.